LLY vs BIIB
By Alex · Tickerpine
Eli Lilly and Company vs Biogen Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | BIIB |
|---|---|---|
| Price | $1,443.50 | $253.40 |
| Market cap | $1.29T | $37.46B |
| P/E ratio | 46.9 | 109.7 |
| ROE | 86.02% | 1.87% |
| Profit margin | 31.90% | 3.38% |
| Revenue growth | 38.60% | 10.60% |
| Dividend yield | 0.48% | 0.00% |
| Beta | 0.39 | 0.09 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs BIIB in plain English
- LLY is the bigger company — about 34.3× the market cap of BIIB.
- LLY is cheaper on earnings (P/E 46.9 vs 109.7).
- LLY earns a higher return on equity (86% vs 2%).
- LLY is growing revenue faster (39% vs 11%).
- LLY pays a dividend (0.48%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
BIIB return calculator
See what $1,000 in Biogen Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.